摘要
Abstract
Objective To observe the clinical efficacy and safety of apatinib combined with chemotherapy in the treatment of advanced gastric cancer.Methods 94 patients with advanced gastric cancer admitted to our hospital from October,2017 to August,2018 were divided into a control group and an observation group according to the random number table method,47 cases for each group.The control group received routine chemotherapy;in addition,the observation group was treated with apatinib.The curative effects,tumor markers,and adverse reactions of the two groups were observed.Results The total effective rate was lower in the control group than in the observation group (31.91％ vs.53.19％,P ＜ 0.05).After the treatment,the levels of CA125 and CEA were lower in the observation group than in the control group [(15.34±2.59) U/ml vs.(33.25±4.52) U/ml and (33.02±5.21) μg/L vs.(57.16±6.24) μg/L,both P ＜ 0.05].The incidences of nausea and vomiting,leukopenia,diarrhea,hypertension,and proteinuria were 51.06％,21.28％,6.38％,8.51％,and 10.64％ in the observation group,and were 42.55％,25.53％,2.13％,4.26％,and 2.13％ in the control group (all P ＞ 0.05).Conclusion Apatinib combined with chemotherapy for patients with advanced gastric cancer can effectively reduce the level of tumor markers and improve the therapeutic effect of single chemotherapy without increasing adverse reactions,so it is safe.关键词
胃癌/阿帕替尼/化疗/疗效/肿瘤标志物/安全性Key words
Gastric cancer/Apatinib/Chemotherapy/Therapeutic effect/Tumor markers/Safety
